ULTRAGENYX PHARMA PLUNGES 45%, HITS ALL-TIME LOW AFTER CO'S RARE DISEASE DRUG FAILS TO MEET MAIN GOAL IN LATE-STAGE TRIAL

Reuters · 2d ago

Please log in to view news